In assessments of clinical importance, although overall expression of IL4I1 and IDO1 is increased in advanced melanoma tumors after treatment with immune checkpoint blockade (ICB)86,87, in ICB-resistant cohorts, the levels of IL4I1 and immune checkpoint molecules, but not IDO1, are elevated18. Here, IDO1 is linked to melanoma.